4CPS-276 Atezolizumab in non-small cell lung cancer: effectiveness and safety real world data study

作者
JJ Alcaraz Sánchez,JC Del Río Valencia,A Pintado Álvarez,B Mora Rodríguez,I Muñoz Castillo
出处
期刊:European Journal of Hospital Pharmacy [BMJ]
卷期号:: A53.1-A53
标识
DOI:10.1136/ejhpharm-2021-eahpconf.108
摘要

Background and importance Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with epidermal growth factor receptor (EGFR) mutant or anaplastic lymphoma kinase (ALK) positive NSCLC should also have received targeted therapies before receiving immunotherapy. Aim and objectives To analyse the effectiveness and safety of treated patients with atezolizumab in usual clinical practice. Material and methods An observational retrospective study was carried out between April 2018 and August 2020. Every patient with squamous and non-squamous NSCLC undergoing treatment with atezolizumab as monotherapy was included. Patient data were obtained from clinical records. Variables analysed were demographic variables (age and sex) and clinical variables (diagnosis, stage, treatment line, dose administered and performance status (PS) according to the ECOG scale). Efficacy endpoints were progression free survival (PFS) and overall survival (OS) assessed by iRECIST criteria and analysed by Kaplan–Meier curves. Adverse reactions were also assessed. Results 35 patients were included, average age 63.52±11.25 years. 8.53% (n=3) had ECOG-PS 2 and the remainder had ECOG-PS 0–1 (n=32). NSCLC stage was IV in 100% (n=35) of patients. 68.57% of patients started therapy with atezolizumab as secondline, 14.29% as thirdline and 17.14% as fourth/fifth line. Only one patient had an EGFR positive mutation. The administered dose was 1200 mg 3 weekly. Four patients (11.43%) were still receiving treatment. Causes of treatment suspension in the remaining patients were disease progression (n=31), death (n=4) or toxicity (n=1). Median PFS was 3.2 months (95% CI 2.6 to 7.2). Median OS was 6.3 months (95% CI 4.4 to 9.1). 40% of patients received ≤3 cycles of treatment. Adverse reactions were: grade 2–3, asthenia 31.43%, grade 1–2 arthralgia 14.29%, anorexia 14.29%, skin toxicity 17.14%, gastrointestinal toxicity 28.57%, pneumonitis 2.86%, hepatic toxicity 8.57%, rheumatological 14.29% and neurological 5.71%. One case of gastrointestinal toxicity caused treatment suspension. Neither renal nor endocrine toxicity was recorded. Conclusion and relevance Median PFS in our study was similar to that found in the OAK phase III trial (2.8 months). Atezolizumab was safe and well tolerated; the safety profile was similar to that described in clinical trials. 40% of patients receiving ≤3 cycles could suggest hyperprogression in a high group of patients. Chemotherapy associated with immunotherapy needs to be studied in this no benefit subgroup of patients. References and/or acknowledgements Conflict of interest No conflict of interest

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
大方的冥茗完成签到 ,获得积分10
2秒前
我是一片云完成签到,获得积分10
2秒前
自然友灵完成签到,获得积分10
2秒前
roking完成签到,获得积分10
2秒前
小马甲的应助被闾丘翠桃采纳,获得10
3秒前
狐狸的贝完成签到,获得积分10
3秒前
3秒前
安详晓亦完成签到,获得积分10
3秒前
3秒前
牛牛完成签到,获得积分10
4秒前
4秒前
coff完成签到,获得积分10
6秒前
7秒前
研友_ZG4ml8发布了新的文献求助10
7秒前
学术的刘完成签到,获得积分10
7秒前
Allen完成签到,获得积分10
8秒前
牧芷珊完成签到,获得积分10
8秒前
阿柠完成签到,获得积分10
8秒前
研友_Zbb4mZ完成签到,获得积分10
8秒前
三七二一完成签到,获得积分10
8秒前
9秒前
JamesPei的应助被爱在西元前采纳,获得10
9秒前
奋斗蝴蝶发布了新的文献求助10
10秒前
陈zw完成签到,获得积分10
10秒前
10秒前
zzzzlllll完成签到,获得积分10
10秒前
Sue完成签到,获得积分10
11秒前
rrr完成签到,获得积分10
11秒前
ZYX完成签到,获得积分10
11秒前
喜悦白玉发布了新的文献求助10
12秒前
ZJ完成签到,获得积分10
12秒前
12秒前
wanci的应助被瘦瘦滢采纳,获得10
12秒前
拉普拉斯开始变换完成签到,获得积分10
12秒前
molihuakai的应助被方苠采纳,获得10
12秒前
feiyue126发布了新的文献求助10
12秒前
13秒前
skmksd发布了新的文献求助10
13秒前
登山者完成签到,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180146
求助须知:如何正确求助?哪些是违规求助? 9570319
关于积分的说明 21809739
捐赠科研通 7776294
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039